liraglutide / Novo Nordisk, Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

77 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
liraglutide / Generic mfg.
2010-019956-32`ACTRN12610000638033: Safety and efficacy of liraglutide as add-on to insulin and metformin therapy in type 2 diabetes patients

Ongoing
4
24
Europe
Suspension for injection, Victoza
Allan Vaag, Steno Diabetes Center
Impacted Wisdom teeth, Inferior Alveolar Nerve injury after third molar removal
 
 
2010-023226-20: Effect of the GLP-1 analogue liraglutide on intragastric pressure and satiation during nutrient drink infusion.

Ongoing
4
20
Europe
Solution for injection, Victoza
KULeuven
healthy volunteersno medical condition; drugs will be studied because they are known to influence gastric motility.
 
 
ChiCTR-IPR-16008578: Analysis of curative effect of Liraglutide monotherapy, Metformin monotherapy and Liraglutide plus Metformin dual therapy in patients with type 2 diabetes mellitus complicated with coronary artery disease

Completed
4
120
 
Liraglutide ;Metformin; high dose Liraglutide; low dose Liraglutide plus Metformin
Tianjin First Center Hospital; Tianjin First Center Hospital, Funding from the department of Endocrinology, Tianjin First Center Hospital
type 2 diabetes mellitus complicated with coronary artery disease
 
 
ChiCTR-OCS-13003185: Plasma cytokine and its tissue expression in different glucose tolerance persons

Completed
4
150
 
GLP-1 receptor agonist
the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.; Level of the institution:, NSFC and Key project of chongqing science and technology commission
diabetes and insulin resistance
 
 
2014-000988-41: Continuous positive airway pressure with or without liraglutide in obstructive sleep apnoea and type 2 diabetes (ROMANCE)

Ongoing
4
152
Europe
Victoza 6mg/ml solution for injection in pre-filled pens, N/A, Solution for injection in pre-filled pen, Victoza 6 mg/ml solution for injection in pre-filled pen
University of Liverpool
Obstructive Sleep Apnoea and Type 2 Diabetes, Obstructive Sleep ApnoeaType 2 Diabetes, Diseases [C] - Hormonal diseases [C19]
 
 
ChiCTR-TRC-14004660: Comparison of efficacy of liraglutide, metformin and gliclazide MR on hepatic lipid content in patients with type 2 diabetes (T2DM) and non-alcoholic fatty liver (NAFLD)

Not yet recruiting
4
63
 
Liraglutide ;Metformin ;Metformin
Drum Tower Hospital Affiliated to Nanjing University Medical School; Drum Tower Hospital Affiliated to Nanjing University Medical School, Drum Tower Hospital Affiliated to Nanjing University Medical School, Novo Nordisk, Merck Serono, Servier, Johnson
Type 2 Diabetes, Non-alcoholic fatty liver
 
 
2013-005395-18: Assessing the efficacy and safety of the GLP1-agonist liraglutide in patients who developed diabetes as a consequence of the use of anti-psychotic drugs Onderzoek naar de effecten van het medicijn liraglutide bij patiënten met een type suikerziekte (diabetes) die veroorzaakt is door het gebruik van antipsychotische medicijnen.

Ongoing
4
50
Europe
Liraglutide, Injection, Liraglutide
University Medical Center Utrecht, University Medical Center
antipsychotic-drugs-associated diabetes mellitus diabetes mellitus veroorzaakt door het gebruik van anti-psychotica, diabetes caused by the use of antipsychotic drugs type suikerziekte die veroorzaakt is door het gebruik van antipsychotische medicijnen, Diseases [C] - Hormonal diseases [C19]
 
 
ChiCTR-TRC-14004996: A clinical study of liraglutide in the treatment of obesity

Recruiting
4
40
 
Once a day liraglutide hypodermic injection ;Oral metformin for three months
The First affiliated Hospital of Zhengzhou University; None, Novo nordisk pharmaceutical co., LTD., China
obesity
 
 

Ongoing
4
80
Europe
LIRAGLUTIDE, Solution for injection, VICTOZA
Imperial College London, MOULTON CHARITABLE FOUNDATION
TYPE 2 DIABETES MELLITUS, DIABETES, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2009-015927-94: Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide?

Ongoing
4
36
Europe
Victoza, Metformin 500mg tablets, Glucophage SR 500 mg prolonged release tablets, Victoza, Metformin 500mg tablets, Glucophage SR 500 mg prolonged release tablets
Hull and East Yorkshire NHS Trust
Polycystic Ovary SyndromeNon-alcoholic Steatohepatitis
 
 
2010-020193-42: A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA\'s)+ high doses of insulin.

Ongoing
4
66
Europe
Victoza (Liraglutide), Glucobay, Victoza (Liraglutide), Victoza, Glucobay, Victoza, Glucobay
Hywel DdA Health Borad
Type-2 Diabetes Mellitus
 
 
2011-003614-17: Treatment of patients with Liraglutide prior to bariatric sugery

Ongoing
4
46
Europe
Victoza®, Victoza®
University Medical Center Hamburg-Eppendorf, University Medical Center Hamburg-Eppendorf
Pretreatment of patients with Type 2 diabetes mellitus with expected weight loss surgery (Roux-en-Y Gastric Bypass)
 
 
2012-005197-63: Effect of liraglutide (antidiabetic drug) on physical performance in patiens with type 2 diabetes. Efecto del tratamiento con liraglutida (medicamento antidiabetico) sobre el rendimiento físico en pacientes con diabetes tipo 2.

Ongoing
4
30
Europe
Victoza, Victoza
Ana M. Wägner, Novo Nordisk A/S
Patients with Diabetes type 2. Pacientes con Diabetes tipo 2.
 
 
2013-005075-40: Effect of Liraglutide on lipid synthesis and metabolism after mixed meal. A single-center randomized controlled study. Liraglutidin vaikutus aterian jälkeiseen rasvojen uudismuodostukseen ja aineenvaihduntaan. -Yhden keskuksen satunnaistettu ja lumelääkekontrolloitu tutkimus.

Ongoing
4
26
Europe
Liraglutide, Liraglutide
Research Programs\' Unit, Diabetes & Obesity, University of Helsinki, Novo Nodisk AG
Type 2 diabetes
 
 
2014-000397-19: Effects of weight reducing surgery and liraglutide on blood glucose in diabetes. Effecten van gewichtsverminderende chirurgie en liraglutide op bloedsuikerwaarden bij diabetes

Ongoing
4
60
Europe
liraglutide, liraglutide
University Medical Center Groningen, Novo Nordisk
type 2 diabetes with morbid obesity type 2 diabetes met morbide obesitas
 
 
2014-003598-41: GLP-1 analogs for Freidreich\'s Ataxia treatment.

Ongoing
4
20
Europe
Victoza, Byetta, Victoza, Byetta, Victoza, Byetta
CUB - Hôpital Erasme, Friedreich's Ataxia Research Alliance
Friedreich\'s Ataxia
 
 
2013-004946-41: correlation between gastric motility and appetite

Ongoing
4
14
Europe
Victoza, Victoza
KULeuven, KULeuven
healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility
 
 
2011-001408-37: Effect of Liraglutide on metabolism and function of the left ventricle in patients with type 2 diabetes and heart problems: study with RMN investigations Effetto della Liraglutide sul metabolismo e sulla funzionalita\' del ventricolo sinistro nei pazienti con diabete di tipo 2 e problemi cardiaci : studio di risonanza magnetica.

Ongoing
4
30
Europe
VICTOZA*SC 2PEN 3ML 6MG/ML, VICTOZA*SC 2PEN 3ML 6MG/ML
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, NOVO NORDISK
patients affected by type 2 diabetes and heart failure pazienti maschi affetti da diabete di tipo 2 e scompenso cardiaco
 
 
2015-005402-11: GLIDE: Gastric band and Liraglutide Intervention in Diabetes Evolution

Ongoing
4
58
Europe
Solution for injection, Victoza 6 mg/ml solution for injection in pre-filled pen
Guys and St Thomas NHS Foundation Trust, Novo Nordisk Ltd
Type 2 Diabetes, Type 2 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2016-001523-31: Effect of liraglutide on vascular inflammation in type-2 diabetes Effekten af Liraglutid på vaskulær inflammation hos patienter med type 2 diabetes

Ongoing
4
100
Europe
Liraglutide, SUB25238, Solution for injection in pre-filled pen, Victoza
Steno Diabetes Center, Novo Nordisk
Type 2 diabetes Type 2 diabetes, Diabetes Sukkersyge, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2017-000043-40: Study of alternative drug to insulin for the treatment of high blood glucose concentration in cardiac surgery patients

Ongoing
4
274
Europe
Solution for injection, VICTOZA
Academic Medical Center, Novo Nordisk
Hyperglyceamia during Cardiac Surgery, High blood glucose concentration in patients undergoing cardiac surgery, Body processes [G] - Physiological processes [G07]
 
 
ChiCTR-IPR-16009666: Effects of liraglutide on inducing long-term clinical remission in newly diagnosed type 2 diabetes after intensive treatment

Recruiting
4
100
 
Liraglutide ;Metformin
Liaocheng City People's Hospital; Liaocheng City People's Hospital, Self-raised funds
Type 2 diabetes
 
 
ChiCTR1800018008: The effects of liraglutide on beta-cell function and its mechanisms in young patients with new-onset type 2 diabetes

Completed
4
60
 
Liraglutide ;Metformin
Department of Endocrinology and Metabolism, Zhongshan Hospital Xiamen University; Zhongshan Hospital Xiamen University, Science and Technology Benefit Fund of Xiamen Technology Bureau
type 2 diabetes
 
 
ChiCTR1800018292: Study for the effect of dapagliflozin combined with insulin pump in type 2 diabetes mellitus

Recruiting
4
87
 
dapagliflozin 10mg/d+ insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d ;insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d.
Teda International Cardiovascular Hospital; Teda International Cardiovascular Hospita, Tianjin Binhai New Area Health and Family Planning Commission science and technology project
Diabetes
 
 
2018-003575-34: Treatment of bile acid malabsorption with liraglutid Behandling af galdesyremalabsorption med liraglutid

Ongoing
4
44
Europe
Injection, Tablet, Victoza, Cholestagel
Professor, Ph.d. MD. Filip Krag Knop, Novo Nordisk
Bile acid malabsoprtion is a disease in which there is a large spill-over of bileacids to the larger intestines. This causes watery diarrheas and abdominal symptoms. Galdesyremalabsorption er en sygdom, hvos der er mere galdesyre i tarmsystemet end hos raske individer. Dette giver vandige diarrere og abdominale gener, Bile acid malabsoprtion is a disease in which there is a large spill-over of bileacids to the larger intestines. This causes watery diarrheas and abdominal symptoms. Galdesyremalabsorption er en sygdom, hvos der er mere galdesyre i tarmsystemet end hos raske individer. Dette giver vandige diarrere og abdominale gener, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR1800017538: Comparison of weight loss in patients with polycystic ovary syndrome of glucophage and liraglutide monotherapy or combination treatment: a randomized controlled trial

Recruiting
4
60
 
Glucophage (Bristol-Myers Squibb) 0.85g Po, bid for 12 weeks ;Liraglutide(Novo Nordisk) 0.6 mg injected s.c. qm for 1 week, and increased to 1.2 mg qd for 11 weeks ;Glucophage (Bristol-Myers Squibb) 0.85g Po, bid for 12 weeks and Liraglutide(Novo Nordisk) 0.6 mg injected s.c. qm for 1 week, and increased to 1.2 mg qd for 11 weeks
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-supporting
Polycystic ovarian syndrome
 
 
2018-001949-13: The effect of a gastrointestinal hormone (GLP-1)agonist on gastrointestinal contractility during the fasted state, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers

Not yet recruiting
4
15
Europe
Liraglutide, Solution for injection in pre-filled pen, Victoza
KU Leuven, KU Leuven
The study will focus on the underlying mechanisms of obesity. The effects will first be investigated in healthy, lean volunteers., The study will focus on the underlying mechanisms of obesity. The effects will first be investigated in healthy, lean volunteers., Body processes [G] - Metabolic Phenomena [G03]
 
 
ChiCTR-OPN-17011066: SNPs Study of DPP4 and GLP1R in Chinese and it's Apply in Blood Glucose Regulation With Incretin.

Recruiting
4
150
 
sitagliptin po 100mg qd ;Liraglutide ih, 0.6mg qd for first week and 1.2mg qd for the last 3 weeks
Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, Science & Technology Department of Sichuan Province
Type 2 diabetes mellitus
 
 
2012-000375-16: Effect of Liraglutide on fatty liver content evaluated by 1H-spectroscopy and lipoprotein kinetic, in patients with type 2 diabetes Effet du Liraglutide sur le contenu en graisse hépatique (évalué par spectroscopie protonique) et sur la cinétique des lipoprotéines chez des patients diabétiques de type 2

Not yet recruiting
4
120
Europe
Solution for injection, VICTOZA
CHU Dijon, NovoNordisk
Diabete type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR1900023036: Glucagon-like Peptide-1 Receptor Agonists Regulating Glucose Metabolism by Regulating Intestinal Flora and its Metabolites: A Prospective, Multi-center Clinical Study.

Not yet recruiting
4
30
 
Liraglutide
Department of Endocrinology and Metabolism, Zhujiang Hospital, Southern Medical University; Zhujiang Hospital, Southern Medical University, Self-financing
Diabetes
 
 
ChiCTR1900023465: Using high-resolution nuclear magnetic technique to observe the effects of liraglutide on visceral function and lipid distribution in type 2 diabetes

Recruiting
4
30
 
Liraglutide ;conventional therapy
Tianjin Metabolic Diseases Hospital; Tianjin Metabolic Diseases Hospital, Tianjin Metabolic Diseases Hospital
Type 2 Diabetes
 
 
ChiCTR1900021593: Comparison of the efficacy and safety of Diane-35 and Drospirenone and Ethinylestradiol Tablets (II) in the treatment of polycystic ovary syndrome: a randomized controlled trial

Not yet recruiting
4
124
 
Diane-35 (2mg ciproterone acetate + 0.035mg ethinylestradiol) for 6 months ;Drospirenone and Ethinylestradiol Tablets (II)(3mg spironetone + 0.002mg ethinylestradiol) for 6 months
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-supporting
Polycystic ovarian syndrome
 
 
ChiCTR2000030904: Effect of liraglutide combined with empagliflozin on β cell function and blood glucose control in newly diagnosed type 2 diabetic patients with overweight or obesity: a randomized parallel controlled trial

Recruiting
4
312
 
Metformin+Empagliflozin ;Metformin+Liraglutide ;Metformin+traditional oral hypoglycemic agents
Sichuan Academy of Medical Sciences•Sichuan Provincial People's Hospital; Sichuan Academy of Medical Sciences?Sichuan Provincial People's Hospital, self-raised funds
Diabetes
 
 
ChiCTR1900020647: Study for GLP-1-based drugs on improving insulin sensitivity in newly diagnosis obese type 2 diabetic patients

Recruiting
4
40
 
Liraglutide+Metformin ;glimepiride+Metformin
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University; The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
diabetes
 
 
2020-002940-22: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL Effetti dell’agonista recettoriale del GLP-1 liraglutide sulla perfusione degli arti inferiori in individui con diabete tipo 2 e arteriopatia periferica: un trial randomizzato controllato

Not yet recruiting
4
50
Europe
Liraglutide, [NA], Solution for injection, VICTOZA - 6 MG/ML-SOLUZIONE INIETTABILE IN PENNA PRERIEMPITA - USO SOTTOCUTANEO - CARTUCCIA(VETRO) IN PENNA PRERIEMPITA - 3ML 2 PENNE PRERIEMPITE
A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
Peripheral Artery Disease and type 2 diabetes mellitus Arteriopatia ostruttiva cronica periferica e diabete mellito tipo 2, Peripheral Artery Disease and type 2 diabetes mellitus Arteriopatia ostruttiva cronica periferica e diabete mellito tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR1900024828: Efficacy of liraglutide combined with insulin pump in type 2 diabetes

Recruiting
4
200
 
Insulin pump combined with liraglutide ;Insulin pump
XuZhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine; XuZhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Self-raised funds
diabetes
 
 
ChiCTR2000034159: The efficacy of Liraglutide in patients with intestinal failure: a prospective, single-center, randomized controlled study

Recruiting
4
60
 
conventional therapy ;Subcutaneous injection of Liraglutide and conventional therapy
Jinling Hospital; Research Institute of General Surgery, Jinling Hospital, the National Natural Science Foundation of China (81470797, 81770531)
Patients with intestinal failure
 
 
ChiCTR1900023294: Effect of insulin sensitizer on psoriasis with metabolic syndrome

Not yet recruiting
4
426
 
Integrated therapy ;Integrated therapy combined with Metformin hydrochloride ;Integrated therapy combined with Liraglutide
Department of Dermatology, Chinese PLA General Hospital; Chinese PLA General Hospital, Fundation on Capital Advantagement of Clinical Application
Psoriasis with metabolic syndrom
 
 
NCT03087032: Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

Recruiting
4
164
RoW
Liraglutide, Victozaa, Liraglutid, Liroglutide, Liraglutidum, Liraglutide Acetate, insulin glargine, Lantus
The First Affiliated Hospital of Xiamen University
Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
01/25
02/25
ChiCTR2000031943: Effect of GLP-1 receptor agonist on intramuscular fat content in obese type 2 diabetic patients

Recruiting
4
94
 
Liraglutide combined with dietary intervention ;Dietary intervention
Beijing Hospital, National Center of Gerontology; Beijing Hospital, National Center of Gerontology, Hospital level topics
diabetes
 
 
NCT04146155: Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease

Recruiting
4
200
RoW
Liraglutide+standard-of-care treatment, Victoza, standard-of-care treatment
Second Affiliated Hospital, School of Medicine, Zhejiang University
Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
12/21
12/21
STARDUST, NCT04881110: Liraglutide and Peripheral Artery Disease

Completed
4
60
Europe
Liraglutide, Intervention group, Control, Control group
University of Campania Luigi Vanvitelli
Type 2 Diabetes, Peripheral Arterial Disease
12/22
12/22
EMPOWER-T2D, NCT04531176: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Terminated
4
74
US
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
The Cleveland Clinic
Type 2 Diabetes, Obesity
08/22
08/23
ChiCTR2000035887: A Randomized controlled trial for liraglutide plus linagliptin in improving neurological function of patients with acute ischemic stroke and hyperglycemia

Not yet recruiting
4
680
 
Liraglutide plus Liraglutide ;Standard hypoglycemic therapy
Shanghai 6th People's Hospital; Shanghai 6th People's Hospital, Shanghai Shenkang Hospital Development Center
acute ischemic stroke
 
 
ChiCTR2000037115: Renal efficacy of liraglutide as add-on to glucose-lowering therapy in patients with biopsy proven type 2 diabetic nephropathy: a multi-center, randomised, open-label trial

Not yet recruiting
4
80
 
liraglutide ;standard treatment
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Special fund
Diabetic Nephropathy
 
 
ChiCTR2000036503: Efficacy of Liraglutide as add-on to glucose-lowering therapy in Patients with biopsy proven Type 2 diabetic nephropathy: a multi-center, randomised, open-label trial

Not yet recruiting
4
156
 
Liraglutide+Standard treatment ;Standard treatment
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Special fund
Diabetic Nephropathy
 
 
ChiCTR2000035772: Efficacy of Liraglutide as add-on to glucose-lowering therapy in Patients with biopsy proven Type 2 diabetic nephropathy: a single-center, randomised, open-label, controlled, trial

Not yet recruiting
4
160
 
subcutaneous injection of liraglutide ;standard therapy
Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Special fund
Diabetic Nephropathy
 
 
Lean-DM, NCT04657939: Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

Completed
4
57
Europe
Liraglutide, Pioglitazone
University of Leeds
Diabetes Mellitus, Type 2
10/22
10/22
NCT06201819: Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

Completed
4
37
RoW
Liraglutide injection
Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca
Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid
03/23
05/23
NCT02344186: Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes

Active, not recruiting
4
12
US
Liraglutide, Victoza
Temple University
Type 2 Diabetes
12/22
12/23
ChiCTR2000031879: A prospective randomized controlled clinical study of liraglutide in preventing fractures in postmenopausal women with type 2 diabetes

Not yet recruiting
4
400
 
Application of liraglutide 1.2-1.8mg once a day, subcutaneous injection ;Do not use liraglutide, use biguanides, insulin secretagogues, αglycosidase inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, SGLT-2 inhibitors, basal insulin
Tongji Hospital, Tongji University School of Medicine; Tongji Hospital, Tongji University School of Medicine, Shanghai Shenkang Hospital Development Center
type 2 diabetes mellitus
 
 
ChiCTR2000036769: A multicenter, randomized, parallel controlled, open-label study on the effects of SGLT2 inhibitor on the renal prognosis of patients with chronic kidney disease with type 2 diabetes

Recruiting
4
300
 
SGLT2i (Dapagliflozin), 5mg qd p.o. ;GLP-1RA (liraglutide), 18 mg/bottle, dosage: once a day, 0.6 mg each time, subcutaneous injection; if there are no obvious adverse reactions, increase to once a day, 1.2 mg each time, before breakfast in the second week Subcutaneous injection; plus dapagliflozin 5mg qd po ;Only use ACEI/ARB, CCB and other antihypertensive drugs, and other antihypertensive drugs
Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 2020 Shenkang Precision Diagnosis and Treatment Project for Intractable Diseases
Diabetic Nephropathy
 
 
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes

Not yet recruiting
4
600
 
DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin)
Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project
Type 2 diabetes
 
 

Not yet recruiting
4
80
 
Use liraglutide to control glucose
Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, 无
sepsis with hyperglycemia
 
 
ChiCTR2200063693: Effect of the glucagon-like peptide-1 receptor agonist on atherosclerosis in patient with impaired glucose tolerance

Not yet recruiting
4
40
 
Intervention to improve life style, including balanced diet (i.e. each person should eat 200g-300g protein, 500g fresh vegetables, 250g Cereals, < 20g vegetable oil, < 6G salt and try to eat less sugar); Regular exercise (i.e. walking for 3 km every day for more than 30 min, at least 5 times a&# ;On the basis of lifestyle improvement intervention, subcutaneous injection of liraglutide / Novolin was given
Qingdao Chengyang District People's Hospital; Chengyang People's Hospital in Qingdao, The Qingdao Medical and health guidance program
impaired glucose tolerance
 
 
ChiCTR2200057797: An observational study of metformin combined with liraglutide in the treatment of polycystic ovary syndrome with insulin resistance

Recruiting
4
30
 
Metformin and liraglutide
Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University, National Natural Science Foundation of China
polycystic ovary syndrome (PCOS)
 
 
ZQL007, NCT03883412: Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( )

Recruiting
4
60
US
Exercise, Liraglutide
University of Virginia, American Diabetes Association, National Institutes of Health (NIH)
Type2 Diabetes
06/25
12/25
ACTRN12617001613392: Effect of liraglutide on weight loss in patients with inadequate weight loss following bariatric surgery

Completed
4
48
 
Monash University, Novo Nordisk
Obesity, Failure of adequate weight loss following Laparoscopic Adjustable Gastric Band
 
 
ChiCTR2100049169: Evaluation of the efficacy of liraglutide or glargine in type 2 diabetes patients combined with malignant tumor which treated with glucocorticoid

Not yet recruiting
4
120
 
glargine ;Liraglutide
Affiliated Cancer Hospital of Chongqing University; Affiliated Cancer Hospital of Chongqing University, Application of blood glucose management system in cancer patients with diabetes mellitus (No.: Jcd201965)
diabetes
 
 
NCT06501326: Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

Recruiting
4
102
RoW
Liraglutide, Orlistat
Affiliated Hospital of Nantong University, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Non-alcoholic Fatty Liver Disease, Obesity
10/24
02/25
NCT03260881: Liraglutide Effects on Epicardial Fat Inflammatory Genes

Completed
4
38
US
Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens
University of Miami, Novo Nordisk A/S
Type2 Diabetes, Coronary Artery Disease
09/24
09/24
ChiCTR2000041308: Research on the clinical efficacy and mechanism of Liraglutide in glucocorticoid-induced hyperglycemia

Recruiting
4
16
 
Liraglutide
Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University, Joint Fund of The Affiliated Hospital of Guizhou Medical University, Guizhou Department of Science and Technology
Hyperglycemia
 
 
ChiCTR2400084794: Efficacy and Safety Analysis of Combined Therapy with Glargine Insulin, Liraglutide, and Metformin in Type 2 Diabetes

Completed
4
87
 
After 7-10 days of intensive insulin pump treatment, the combination of insulin glargine, metformin hydrochloride and liraglutide was given; After 7-10 days of intensive insulin pump therapy, metformin hydrochloride, daglipzin and acarbose were given combined therapy
Guangrao County People's Hospital of Dongying city; Department of Endocrinology, Guangrao County People's Hospital of Dongying city, Department of Endocrinology, Guangrao County People,s Hospital of Dongying city
Type 2 Diabetes
 
 
ChiCTR2200060695: Effect of pioglitazone metformin combination with liraglutide in patients with type 2 diabetes complicated with metabolometabolic fatty liver disease

Recruiting
4
147
 
Pioglitazone metformin tablets ;Liraglutide injection ;Pioglitazone metformin tablets + Liraglutide injection
Shandong Provincial Hospital; Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd., Hangzhou ZhongMei Huadong Pharmaceutical Co., Ltd.
Type 2 diabetes mellitus with metabolism-related fatty liver disease
 
 
LEAF, NCT03856632: Liraglutide Effect in Atrial Fibrillation

Active, not recruiting
4
60
US
Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
University of Miami
Atrial Fibrillation
12/24
12/24
ChiCTR1900026485: Efficacy and safety of liraglutide in the treatment of newly-diagnosed overweight / obesity type 2 diabetes mellitus: a single-center, randomized, parallel controlled trial

Not yet recruiting
4
192
 
liraglutide; metformin
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Affiliated Hospital of Guangdong Medical University
newly-diagnosed overweight / obesity type 2 diabetes mellitus
 
 
ChiCTR2300074947: Effect of liraglutide on depressive status in patients with type 2 diabetes mellitus and major depressive disorder: a single-center, observational cohort study

Not yet recruiting
4
100
 
NA; NA
Peking University, Third Hospital; Peking University, Third Hospital, N/A
type 2 diabetes mellitus and major depressive disorder
 
 
LITOP, NCT06742710: Liraglutide Treatment in Obese Infertile PCOS Women

Not yet recruiting
4
890
NA
Liraglutide and metformin, Metformin
Peking University Third Hospital
PCOS, Obesity, Infertility
06/28
06/28
ZQL008, NCT04575844: Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Recruiting
4
80
US
Liraglutide, Exercise training, Liraglutide + Exercise training
University of Virginia, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Syndrome
04/25
04/25
ChiCTR2300078600: Effects of GLP-1 receptor agonists on glucose metabolism and its complications in patients with new-onset diabetes after renal transplantation: a prospective randomized controlled trial

Not yet recruiting
4
196
 
Administration of Liraglutide; Administration of Metformin
Beijing Chao-yang Hospital, Capital Medical University; Beijing Chao-yang Hospital, Capital Medical University, Supported by Beijing Municipal Science & Technology Comission NO.Z221100007422029
new-onset diabetes after renal transplantation
 
 
ChiCTR2400081365: The effect of Henggeliflozin on skeletal muscle of overweight and obese type 2 diabetic patients with poor blood sugar control

Not yet recruiting
4
60
 
Oral administration of Henggeliflozin; Subcutaneous injection of Liraglutide
Shaanxi Provincial People's Hospital; Shaanxi Provincial People's Hospital, International diabetes Exchange and Practice Fund
Type 2 diabetes
 
 
ChiCTR2400090984: A Multicenter, Prospective, Observational Study of Liraglutide Injection (Rilupine) in the Treatment of Overweight or Obese Patients

Recruiting
4
3000
 
Nanchang First Hospital; Nanchang First Hospital, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd
overweight or obese
 
 
ChiCTR2400088178: Observation and mechanism of liraglutide in the treatment of obese/overweight patients with type 2 diabetes mellitus complicated with depression

Not yet recruiting
4
60
 
At the same time as the basic treatment of diabetes, liraglutide injection (0.6 mg/day at the beginning, adjusted to 1.2 mg/day after one week);; For the basic treatment of diabetes, other hypoglycemic drugs can be added, and no drugs containing GLP-1 related preparations can be added.
Chengdu Shuangliu District Traditional Chinese Medicine Hospital; Chengdu Shuangliu District Hospital of Traditional Chinese Medicine, Horizontal funding
type 2 diabetes mellitus
 
 
ChiCTR2400083284: Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Single-Center Randomized Controlled Study

Not yet recruiting
4
260
 
Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.; Subcutaneous injection of vehicle: the same volume as liraglutide administrated at the corresponding times.
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
Postoperative Delirium
 
 
ChiCTR2400089328: A randomized controlled study of liraglutide in intensive hypoglycemic treatment of elderly critically ill patients with hyperglycemia

Not yet recruiting
4
212
 
Application of GLP-1 on the basis of intensive insulin therapy; Intensive insulin therapy
Xiangyang Central Hospital; Xiangyang Central Hospital, raise independently
212 elderly critically ill patients with hyperglycemia admitted to the intensive care unit of the Department of geriatrics in Xiangyang central hospital were selected as the research objects.
 
 
NCT05681299: Effects of GH and Lirglutide on AgRP

Recruiting
4
40
US
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Columbia University
Healthy, Growth Hormone Deficiency
04/28
04/28
2017-000349-30: Effect of INtervention with DMR, GLP-1 and lifestyle intensification -in Subjects with insulin dePendent type 2 diabetes- on Insulin Requirement and mEtabolic parameters Effect van interventie met DMR, GLP-1 en lifestyle intensivering -bij patiënten met insulineafhankelijke type 2 diabetes- op insulinebehoefte en metabole parameters

Ongoing
3/4
16
Europe
Victoza, EMA/354054/2016, Solution for injection in pre-filled pen, Victoza (Liraglutide)
Academic Medical Center, Fractyl Laboraties Inc.
Type 2 diabetes mellitus Diabetes mellitus type 2, Type 2 diabetes Suikerziekte type 2, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 

Download Options